Balancing Caution and Patient Care
U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced a new effort on May 4 to reduce overprescription of certain psychiatric medications, specifically targeting selective serotonin reuptake inhibitors (SSRIs)—a class of drugs that includes Lexapro, Prozac, and Zoloft. The initiative, announced during a speech at the MAHA Institute summit on mental health and overmedicalization, encourages providers to prioritize informed consent and consider “nonmedication approaches” like family support, psychotherapy, nutrition, and physical activity.
Decreasing unnecessary medication dependence could be appropriate depending on the patient, disorder, and other clinical variables, which only a prescribing physician can effectively manage. According to the National Institutes of Health, more than 13% of Americans filled antidepressant prescriptions post-pandemic. A 2025 study published in The Lancet examined the side effects of 30 antidepressants across 151 clinical trials and 17 FDA reports, concluding that modern formulations like SSRIs have fewer and less serious side effects than older medications.
Concerns About Regulatory Overreach
Concerns arise given prior initiatives from Kennedy’s Make America Healthy Again movement. Most recently, CDC Director Dr. Jay Bhattacharya blocked publication of a study showing COVID shots contributed to a material reduction in hospital visits. Previous efforts also restricted COVID vaccinations, overhauled advisory panels, and modified childhood vaccination schedules. Guidelines and recommendations on overmedication are welcome, but care providers must retain discretion when selecting treatment options, and patients must have final say in their care decisions.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.staradvertiser.com/2026/05/11/editorial/our-view/editorial-follow-experts-on-psychiatric-drugs/